CMPX - CIK 0001738021
Compass Therapeutics, Inc. trades as CMPX. In its fiscal 2025 annual report the company posted revenue of $0.00, down 100.0% from the prior year and net income of -$66.49M. This page tracks Compass Therapeutics, Inc. through 349 SEC filings, with financial statements and metrics updated as new reports are filed.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G/A | - | 2026-05-15 |
| Quarterly report | 10-Q | 2026-05-05 |
| Major company event | 8-K | 2026-05-05 |
| Insider trade (amended) | 4/A | 2026-04-30 |
| Insider trade (amended) | 4/A | 2026-04-30 |
| Insider trade | 4 | 2026-04-29 |
| Insider trade | 4 | 2026-04-29 |
| Annual report to shareholders | ARS | 2026-04-29 |
The largest companies sharing Compass Therapeutics, Inc.'s SEC industry classification (biological products, (no diagnostic substances)).
Compass Therapeutics, Inc. reported revenue of $0.00 for fiscal year 2025, a decrease of 100.0% year over year.
In its latest fiscal year Compass Therapeutics, Inc. reported a net loss of $66.49M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.